Two days later.

"Mr. Chen, I have notified several other shareholders, including only Minister Chen, who is in charge of the sales department and Minister Zhao, who is in charge of the personnel department, are willing to maintain the share ratio and continue to follow up the investment. The remaining shareholders are unwilling to increase their investment."

Among Ruikang Medical's shares, 86.5% belongs to the Chen family, and are now under Chen Changan's name.

The remaining 14.5% are mostly divided into several other management teams who started their business with Lao Chen. Before Chen Changan officially took over Ruikang, they were all "retired" one after another under the care of Lao Chen.

Only Chen Yun, who is in charge of the sales department and Zhao Liuqing, who is in charge of the personnel department, were senior executives who were later abandoned by Chen, who was recruited from other companies. He divided some management stocks, accounting for about 4.8% of them.

Their vision is still very forward-looking. In their opinion, Ruikang's current development is very smooth. After improving its sales network and establishing its own R&D system, its future prospects are still very good.

They have also participated in Ruikang's operations in the past two or three years, especially Chen Yun. He is responsible for all Ruikang's sales matters and is very clear about the company's profit growth.

Zhao Liuqing was very confident in the scientific researchers recruited by Chen Changan.

The two are only in their thirties now, and their fighting spirit is still very passionate, so they are naturally willing to choose to continue to invest in holding shares.

Now Ruikang's shares are all original shares. If the company goes public in the future, each share is worth a lot of money, so naturally it will not be diluted without being diluted.

Compared to the old backbones who were competing with Lao Chen for their career, both of them have much more education and ability, so they can naturally make more correct choices.

After the increase in holdings, Chen Changan's current shares of Ruikang Medical have increased from 86.5% to 91%.

Zhao Liuqing and Chen Yun remained unchanged at 4.8%, while the remaining 4.2% was controlled by the remaining old backbones.

Chen Changan sat on the office chair and shook it. After thinking about it for a while, he simply said:

"Guan Kou, you can help me ask. Since they are willing to dilute the shares in their hands, it's better to sell them to me directly. I can buy back the 4.2% shares at a premium."

"I believe that someone will be moved by this price."

After the shares are diluted, 4.2% of the shares are only worth about 100 million yuan based on Ruikang's total share capital. If Chen Changan acquires it at a premium of 120 million yuan, those short-sighted old backbones will likely choose to sell it.

If he has a premium of 150 million yuan, he should be able to handle the remaining scattered shares.

The reason why he was anxious to concentrate Ruikang's shares back to his hands was because he was planning to complete the A round.

In fact, under normal circumstances, when Ruikang's fish skin collagen was listed online, the company could start round A financing, because at that time, Ruikang's cash flow could not keep up with the company's development and enrollment expansion speed.

It was just because Chen Changan got a loan from ICBC that he supported him.

Later, when the Youchuang ventilator was launched, Ruikang faced the second problem of insufficient capital chain. The national sales network could not be opened at all, and the after-sales service was even worse, and there was not much money to invest in sales promotion.

However, because of Medtronic's incident, Chen Changan simply stripped the Kirin Invasive Ventilator from Ruikang Medical and established a joint venture with Mindray and other companies.

The sales channels and funds were filled by several other domestic ventilator manufacturers, so he once again suspended the financing.

But now I can't delay it anymore.

The next Ruikang project, whether it is a biological pacemaker or an artificial hematopoietic machine, requires a lot of funds to support the launch of the product.

With the preliminary preparations alone, infrastructure construction has been spent almost 400 million yuan, plus Chen Changan's investment of 200 million yuan.

The product has been developed and has burned 600 million yuan.

The subsequent production, transportation chain, promotion and other links still require a lot of financial support. Conservatively, it may also require billions of working capital.

After all, whether it is a biological pacemaker or a blood manufacturing machine, they are equipment that has never been available in the medical industry. It is impossible to promote this new product without spending enough money.

In the medical industry, it is not new technology that is good, it is not like selling mobile phones, everyone likes the latest models.

Most of the medical industry purchases medical equipment in order to be stable and will not easily try a brand new product.

Medtronic's latest pacemaker has just made some innovations, removed the wires, and reduced the volume by 92% compared to traditional pacemakers.

If you want to say whether the technology is good? Of course it is good!

Is advanced or not? Of course it is very advanced, and it can even be said to be the epoch-making type.

However, even though Medtronic has vigorously promoted this new pacemaker for four or five years, participated in the World Expo, World Advance, and various international science and technology exhibitions, it has not been popular yet.

in the country, some hospitals have purchased some of the first-tier cities such as Beijing, Shanghai, Guangzhou and Shenzhen.

In the medical industry, the more advanced and advanced equipment is, the slower it will be promoted, especially when it comes to things such as heart and blood transfusions that are related to human life.

It is impossible to be accepted by the public without going through several years of clinical tests.

It is impossible to sell everything like a technology product, and sell it out as soon as it is launched, and inventory is exhausted, and it is overwhelming to buy it.

Even if Chen Changan announced the development of a longevity potion, one injection can extend the life span of ten years, it will not trigger an injection frenzy as soon as it is launched.

Without five or six years of public experiments and not enough cases to prove that no one would believe it.

Human beings are the most dear creatures. It is not an exaggeration to be careful about anything that involves one's own life.

Patients would rather choose traditional mechanical pacemakers that have been used by tens of millions of people, proving that they can indeed effectively treat themselves.

Even if he is big, troublesome, and requires surgery, there are still many follow-up precautions after implantation.

They will not be willing to try new bio pacemakers. Even if the publicity is good, they will not use them for reasons before there are enough cases to prove that they are safe and reliable.

Even doctors will not risk recommending patients, because new technologies often represent high risks, and neither patients nor doctors are willing to take this high risk.

Chen Changan had already anticipated this situation, so he had to prepare enough funds in advance to deal with this situation.

In the first three years of the launch of bio pacemakers and blood makers, it will not only not be the day when the company starts to make a profit, but will instead be a day when it costs a lot of money.

If the company does not raise a large amount of funds to support it, it may not be able to survive this difficult period.

Fortunately, at least Chen Changan doesn’t have to spend a lot of money to try and make mistakes during the scientific research stage. He can still support himself by gritting his teeth, which is much more comfortable than other medical companies.

He still has enough time to do the valuation of Gaoruikang Medical. After all, the difference between the valuation before the successful development of bio pacemakers and blood manufacturing machines and the valuation after the successful development is not a little bit.

There can even be a tenfold gap!

"Guan Kou, after acquiring the remaining shares of the company, your next main task is to contact some large venture capital companies. We need to start preparing for the A round of financing."

"Value companies such as Goldman Sachs, Sequoia, SoftBank, etc. can all contact us to see if they are willing to invest in our A round."

"Try them to see what their valuation of Ruikang."

After Chen Changan gave Guan Kou a few words lightly, he added: "Ask about the situation first, don't rush to discuss specific matters, just find out."

"Okay, Mr. Chen." Guan Kou nodded and wrote down Chen Changan's instructions in his notebook.

"Yeah." Chen Changan nodded with satisfaction. Guan Kou, the administrative secretary, was really conscientious and useful. With her help, Chen Changan was at least half relieved.

If it weren't for the Reincarnation, he wouldn't have escaped from the company's busy daily routines, let alone entered the laboratory to take the lead in scientific research.

After looking at Guan Kou who was carefully checking his work record book, Chen Changan said with a smile: "Guan Kou, you go and prepare an equity transfer agreement."

Guan Kou recorded another task on his small notebook without raising his head. While writing, she also asked: "Mr. Chen, what is the transfer ratio, and who are the transferor and the transferor."

"The ratio is 2%, so it is naturally me who sends the person. Please fill in your name with the transferee."

"ah??"

Guan Kou's hand holding the pen trembled slightly, and he raised his head and looked at Chen Changan in shock.

"What are you looking at? Remember carefully. Once the transfer agreement is drafted, I will sign it."

Chen Changan looked at Guan Kou's confused look and laughed out loud. This was the first time he saw Guan Kou's misconduct.

Very interesting!
Chapter completed!